[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100592233":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":31,"centralContacts":35,"locations":26,"responsibleParty":41,"collaborators":26,"id":45,"slug":46,"hasResults":47,"nctId":48,"briefTitle":49,"officialTitle":50,"acronym":26,"eligibilityCriteria":51,"healthyVolunteers":47,"sex":52,"minAge":53,"maxAge":54,"enrollmentInfo":55,"targetDuration":26,"studyType":58,"phases":59,"briefSummary":61,"conditions":62,"keywords":64,"overallStatus":67,"whyStopped":26,"lastUpdateSubmitDate":68,"lastUpdatePostDateStruct":69,"startDateStruct":72,"completionDateStruct":74,"leadSponsor":76,"locationsCount":26},{"fullName":5,"class":6},"Second Hospital of Shanxi Medical University","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Remimazolam group","EXPERIMENTAL","Remimazolam was used for anesthesia induction and maintenance",[13],"Drug: Remimazolam",{"label":15,"type":16,"description":17,"interventionNames":18},"Propofol group","ACTIVE_COMPARATOR","Anesthesia induction and maintenance were carried out using propofol",[19],"Drug: propofol",[21,27],{"type":22,"name":23,"description":24,"armGroupLabels":25,"otherNames":26},"DRUG","Remimazolam","Remimazolam, sufentanil and rocuronium were used during induction, and remimazolam and refentanil were used during maintenance",[9],null,{"type":22,"name":28,"description":29,"armGroupLabels":30,"otherNames":26},"propofol","Propofol, sufentanil and rocuronium were used during induction, and propofol and remifentanil were used during maintenance",[15],[32],{"name":33,"affiliation":5,"role":34},"yi Han","STUDY_DIRECTOR",[36],{"name":37,"role":38,"phone":39,"phoneExt":26,"email":40},"ran Zhang","CONTACT","17835158352","17835158352@163.com",{"type":42,"investigatorFullName":43,"investigatorTitle":44,"investigatorAffiliation":5,"oldNameTitle":26,"oldOrganization":26},"PRINCIPAL_INVESTIGATOR","Zheng Guo","professor","100592233","network-pharmacology-was-applied-to-explore-the-mechanism-of-remimazolam-applied-in-general-anesthesia-for-gynecological-surgeries-100592233",false,"NCT06990763","Network Pharmacology Was Applied to Explore the Mechanism of Remimazolam Applied in General Anesthesia for Gynecological Surgeries","Clinical and Molecular Mechanism Study of Remimazolam Regulating the N\u002FOFQ-inflammation-immune Axis to Optimize the Effect of General Anesthesia in Gynecological Surgery","Inclusion Criteria:\n\n1. The patient or their family members sign the informed consent form\n2. Age: 18-64 years old, BMI: 18-30kg\u002Fm2\n3. ASA Grade Ⅰ or Ⅱ\n4. Patients undergoing gynecological surgeries (laparoscopic total hysterectomy, adnexectomy and myomectomy)\n\nExclusion Criteria:\n\n1. People who are allergic to remimazolam or benzodiazepinesThyroid disease\n2. Long-term use of benzodiazepines\n3. Pregnancy or lactation\n4. Have a history of drug abuse or alcoholism\n5. Patients with contraindications for surgery\n6. Patients with hypertension (clinically diagnosed with hypertension) and patients with coronary heart disease (with typical angina pectoris symptoms and excluding aortic valve lesions, with a clear history of old myocardial infarction, with a clear history of acute myocardial infarction, and CAG finding coronary artery stenosis greater than or equal to 70%)\n7. Patients with arrhythmia, heart failure, renal failure, and those who have recently taken cardiovascular active drugs\n8. Endocrine disorders such as hyperthyroidism and pheochromocytoma that may affect the hemodynamic level of the body\n9. Patients with ketoacidosis and lactic acidosis\n10. Abnormal liver function, ALT\\> three times the upper limit of the normal value;\n11. Renal failure (serum creatinine \\>3mg\u002Fdl or creatinine clearance rate \\\u003C30ml\u002Fmin)\n12. Patients who have been using sedatives or antidepressants for a long time, or have a history of alcohol abuse or drug dependence\n13. Asthma or reactive airway diseases\n14. Combined with underlying cognitive function abnormalities\n15. Exclusion criteria for research subjects\n16. Those who were mistakenly included without meeting the inclusion criteria\n17. Those who experienced adverse events such as shock, severe hypotension and severe arrhythmia during the operation","FEMALE","18 Years","64 Years",{"count":56,"type":57},40,"ESTIMATED","INTERVENTIONAL",[60],"NA","To explore the related mechanisms by which remimazolam regulates hemodynamic stability, inflammatory factors and the immune system in patients undergoing general anesthesia for gynecological surgeries.",[63],"Gynecological Disease",[65,28,66],"remimazolam","gynecological disease","NOT_YET_RECRUITING","2025-05-17",{"date":70,"type":71},"2025-05-25","ACTUAL",{"date":73,"type":57},"2025-06-01",{"date":75,"type":57},"2026-01-01",{"name":5,"class":6}]